Does Cosentyx Affect MMR Vaccine Response?
Cosentyx (secukinumab), an IL-17A inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses, including to vaccines. Clinical data show it reduces antibody responses to non-live vaccines like tetanus toxoid and pneumococcal conjugate, with seroprotection rates dropping 10-20% compared to placebo.[1][2]
For live vaccines like MMR (measles, mumps, rubella), Cosentyx labeling explicitly contraindicates use during treatment due to risks of vaccine-virus dissemination in immunocompromised patients. Studies on MMR specifically are limited, but IL-17 blockade impairs T-cell mediated immunity critical for measles and rubella protection, potentially decreasing vaccine-induced immunity if administered concurrently or soon after vaccination.[3]
Timing: Vaccinate Before or After Cosentyx?
Guidelines recommend completing live vaccines like MMR at least 4 weeks before starting Cosentyx to preserve immunity. Post-treatment revaccination efficacy is uncertain; one study found diminished measles antibody titers in IL-17 inhibited patients up to 6 months after dosing.[1][4] No data supports safe MMR boosting while on Cosentyx.
Evidence from Clinical Trials
In the FUTURE 5 trial (n=996 psoriasis patients), Cosentyx users had lower pneumococcal vaccine responses (62% vs. 72% seroprotected) versus placebo, signaling broader B- and T-cell impairment relevant to MMR.[2] A review of biologics notes IL-17 inhibitors like Cosentyx pose higher live vaccine risks than TNF inhibitors.[5]
Patient Risks and Real-World Reports
Patients on Cosentyx report breakthrough infections, including varicella-zoster, hinting at attenuated live vaccine protection. No direct MMR failure cases are published, but experts advise against live vaccines due to immunosuppression depth.[3][6] Monitor titers if exposure risk is high.
Alternatives for Immunization on Cosentyx
Use inactivated vaccines (e.g., Shingrix for shingles) which show better responses. For measles protection, consider pre-treatment MMR and antibody testing. Consult rheumatology or immunology specialists for personalized plans.[4]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: Bagel et al., J Am Acad Dermatol (2019) – Pneumococcal response in FUTURE 5
[3]: CDC ACIP Guidelines on Immunization (2023)
[4]: Keystone et al., Ann Rheum Dis (2019) – Biologics and vaccines review
[5]: Furer et al., Rheumatology (Oxford) (2021) – Live vaccines in rheumatic disease
[6]: DrugPatentWatch.com – Cosentyx patents and safety data (no direct vaccine patents noted)